MCID: MCS004
MIFTS: 49

Mucosal Melanoma

Categories: Cancer diseases, Skin diseases

Aliases & Classifications for Mucosal Melanoma

MalaCards integrated aliases for Mucosal Melanoma:

Name: Mucosal Melanoma 12 29 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:0050929
UMLS 73 C3898222

Summaries for Mucosal Melanoma

Disease Ontology : 12 A melanoma that has material basis in melanocytes located in mucosal membranes lining the respiratory, gastrointestinal and urogenital tract.

MalaCards based summary : Mucosal Melanoma is related to melanoma and skin melanoma. An important gene associated with Mucosal Melanoma is KIT (KIT Proto-Oncogene Receptor Tyrosine Kinase), and among its related pathways/superpathways are Signaling by GPCR and Apoptotic Pathways in Synovial Fibroblasts. The drugs Nicotinamide and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and lymph node, and related phenotypes are endocrine/exocrine gland and growth/size/body region

Wikipedia : 76 Mucosal melanoma is a rare cutaneous condition characterized by a melanoma of the mucous... more...

Related Diseases for Mucosal Melanoma

Diseases related to Mucosal Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 75)
# Related Disease Score Top Affiliating Genes
1 melanoma 32.1 BRAF MAGEC1 MITF NRAS
2 skin melanoma 29.9 BRAF MITF NRAS
3 malignant skin fibrous histiocytoma 29.8 KIT NRAS
4 acral lentiginous melanoma 29.5 BRAF KIT NRAS TERT
5 ovarian melanoma 10.2 KIT NRAS
6 conventional fibrosarcoma 10.2 KIT NRAS
7 amelanotic melanoma 10.2 BRAF KIT
8 erdheim-chester disease 10.2 BRAF NRAS
9 congenital mesoblastic nephroma 10.2 KIT NRAS
10 phakomatosis cesioflammea 10.2 GNA11 GNAQ
11 intraocular melanoma 10.2 GNA11 GNAQ
12 urachal adenocarcinoma 10.2 BRAF NF1
13 nodular malignant melanoma 10.2 GNAQ NRAS
14 plexiform schwannoma 10.2 KIT NF1
15 core binding factor acute myeloid leukemia 10.1 KIT NRAS
16 pilocytic astrocytoma of cerebellum 10.1 BRAF NF1
17 pilocytic astrocytoma 10.1 BRAF NF1
18 malignant dermis tumor 10.1 KIT NRAS
19 spermatocytoma 10.1 KIT MAGEC1
20 neurofibromatosis, type i 10.1 KIT NF1
21 myelodysplastic myeloproliferative cancer 10.1 NF1 NRAS
22 ocular melanoma 10.1 IL2 KIT
23 maxillary sinus adenoid cystic carcinoma 10.1 IL2 KIT
24 leopard syndrome 10.1 BRAF NF1
25 pilomyxoid astrocytoma 10.1 BRAF NF1
26 mast cell neoplasm 10.1 IL2 KIT
27 malignant conjunctival melanoma 10.0 GNA11 GNAQ NRAS
28 melanomatosis 10.0 GNA11 GNAQ NRAS
29 conjunctival cancer 10.0 GNA11 GNAQ NRAS
30 meningeal melanomatosis 10.0 GNA11 GNAQ NRAS
31 meningeal melanocytoma 10.0 GNA11 GNAQ NRAS
32 nervous system benign neoplasm 10.0 KIT NF1
33 gastrointestinal stromal tumor 10.0 BRAF KIT NF1
34 cutaneous ganglioneuroma 10.0 KIT MITF
35 juvenile myelomonocytic leukemia 10.0 BRAF NF1 NRAS
36 posterior uveal melanoma 10.0 BRAF MITF
37 pulmonic stenosis 10.0 BRAF NF1
38 breast angiosarcoma 10.0 KIT MITF
39 thymus gland disease 10.0 IL2 KIT
40 dowling-degos disease 1 10.0 KIT MITF
41 central nervous system melanocytic neoplasm 9.9 GNA11 GNAQ KIT NRAS
42 ocular cancer 9.9 GNA11 GNAQ IL2
43 lymphoma 9.9
44 thyroid cancer 9.9 BRAF KIT NRAS TERT
45 lymphoma, non-hodgkin, familial 9.9 BRAF IL2 NRAS
46 neurofibroma 9.9 KIT MITF NF1
47 vulvar melanoma 9.9 KIT NF1 NRAS TERT
48 myelodysplastic syndrome 9.8 KIT NF1 NRAS TERT
49 angiomyolipoma 9.8 KIT MITF
50 noonan syndrome 1 9.8 BRAF IL2 NF1 NRAS

Graphical network of the top 20 diseases related to Mucosal Melanoma:



Diseases related to Mucosal Melanoma

Symptoms & Phenotypes for Mucosal Melanoma

MGI Mouse Phenotypes related to Mucosal Melanoma:

46 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.23 BRAF GNA11 GNAQ IL2 KIT MITF
2 growth/size/body region MP:0005378 10.22 BRAF GNA11 GNAQ IL2 KIT MITF
3 behavior/neurological MP:0005386 10.21 BRAF GNA11 GNAQ IL2 KIT MITF
4 hematopoietic system MP:0005397 10.2 BRAF GNA11 GNAQ IL2 KIT MITF
5 homeostasis/metabolism MP:0005376 10.19 BRAF GNA11 GNAQ IL2 KIT MITF
6 immune system MP:0005387 10.18 BRAF GNA11 GNAQ IL2 KIT MITF
7 cardiovascular system MP:0005385 10.15 BRAF GNA11 GNAQ IL2 KIT NF1
8 cellular MP:0005384 10.14 BRAF IL2 KIT MITF NF1 NRAS
9 craniofacial MP:0005382 10.14 BRAF GNA11 GNAQ KIT MITF NF1
10 mortality/aging MP:0010768 10.11 BRAF GNA11 GNAQ IL2 KIT MITF
11 digestive/alimentary MP:0005381 10.06 BRAF IL2 KIT NF1 NRAS TERT
12 integument MP:0010771 10.05 BRAF GNA11 GNAQ KIT MITF NF1
13 limbs/digits/tail MP:0005371 10.04 BRAF GNA11 GNAQ KIT MITF NF1
14 hearing/vestibular/ear MP:0005377 10.03 BRAF GNA11 GNAQ KIT MITF NF1
15 normal MP:0002873 9.97 BRAF GNA11 GNAQ KIT MITF NF1
16 liver/biliary system MP:0005370 9.95 BRAF GNA11 IL2 KIT NF1 NRAS
17 nervous system MP:0003631 9.95 BRAF GNA11 GNAQ KIT MITF NF1
18 neoplasm MP:0002006 9.91 BRAF IL2 KIT NF1 NRAS TERT
19 pigmentation MP:0001186 9.87 BRAF GNA11 GNAQ KIT MITF NF1
20 respiratory system MP:0005388 9.7 BRAF GNA11 GNAQ IL2 KIT NF1
21 renal/urinary system MP:0005367 9.65 BRAF GNA11 GNAQ KIT NF1
22 skeleton MP:0005390 9.56 BRAF GNA11 GNAQ KIT MITF NF1
23 vision/eye MP:0005391 9.1 BRAF IL2 KIT MITF NF1 NRAS

Drugs & Therapeutics for Mucosal Melanoma

Drugs for Mucosal Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 74)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotinamide Approved, Investigational Phase 3 98-92-0 936
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 2 33069-62-4 36314
3
Sorafenib Approved, Investigational Phase 3 284461-73-0 216239 406563
4
Carboplatin Approved Phase 3,Phase 2 41575-94-4 10339178 38904 498142
5
Pembrolizumab Approved Phase 3,Phase 2,Phase 1 1374853-91-4
6
Temozolomide Approved, Investigational Phase 3 85622-93-1 5394
7
Dacarbazine Approved, Investigational Phase 3 4342-03-4 5351166
8
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
9
Niacin Approved, Investigational, Nutraceutical Phase 3 59-67-6 938
10
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
11
Imidacloprid Vet_approved Phase 3 105827-78-9 86418
12 Micronutrients Phase 3
13 Folate Phase 3
14 Nicotinic Acids Phase 3
15 Vitamin B9 Phase 3
16 Trace Elements Phase 3
17 Vitamins Phase 3
18 Antimitotic Agents Phase 3,Phase 2
19 Vitamin B3 Phase 3
20 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
21 Vitamin B Complex Phase 3
22 Albumin-Bound Paclitaxel Phase 3,Phase 2
23 Protein Kinase Inhibitors Phase 3,Phase 2
24 Immunologic Factors Phase 3,Phase 2,Phase 1
25 Antibodies Phase 3,Phase 2,Phase 1
26 Immunoglobulins Phase 3,Phase 2,Phase 1
27 Antineoplastic Agents, Alkylating Phase 3
28 Antiviral Agents Phase 3,Phase 2
29 Interferon-alpha Phase 3,Phase 2
30 Anti-Infective Agents Phase 3,Phase 2
31 Alkylating Agents Phase 3
32 Krestin Phase 3
33 interferons Phase 3,Phase 2,Phase 1
34 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
35
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
36
Nivolumab Approved Phase 2,Phase 1 946414-94-4
37
Bevacizumab Approved, Investigational Phase 2 216974-75-3
38
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
39
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
40
Everolimus Approved Phase 2 159351-69-6 6442177
41
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
42
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
43
Serine Approved, Nutraceutical Phase 2 56-45-1 5951
44 tyrosine Phase 2
45 Imatinib Mesylate Phase 2 220127-57-1 123596
46 Angiogenesis Modulating Agents Phase 2
47 Angiogenesis Inhibitors Phase 2
48 Vaccines Phase 2,Phase 1
49 Freund's Adjuvant Phase 2,Phase 1
50 Adjuvants, Immunologic Phase 2

Interventional clinical trials:

(show all 41)
# Name Status NCT ID Phase Drugs
1 Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Completed NCT00110019 Phase 3 Carboplatin;Paclitaxel;Sorafenib Tosylate
2 HDI Versus Chemotherapy as Systemic Adjuvant Therapy for Resected Mucosal Melanoma Recruiting NCT03435302 Phase 3 Temozolomide Plus Cisplatin;High-Dose IFN-a2b
3 High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery Active, not recruiting NCT02506153 Phase 3
4 A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread Completed NCT01395121 Phase 2 nilotinib
5 Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma Completed NCT00424515 Phase 2 Imatinib
6 Trial of Imatinib (Gleevec®) in Selected Patients With Metastatic Melanoma Completed NCT00881049 Phase 2 Imatinib (Gleevec)
7 SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma Completed NCT00577382 Phase 2 Sunitinib
8 Study of Nilotinib in Metastatic Melanoma With KIT Aberrations Completed NCT01099514 Phase 2 Nilotinib
9 THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease Completed NCT01355120 Phase 2 Ipilimumab
10 Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma Completed NCT01961115 Phase 2 Epacadostat
11 Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma Completed NCT00085189 Phase 2 Montanide ISA 51 VG;agatolimod sodium
12 The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery Recruiting NCT03178123 Phase 2
13 Mucosal Melanoma of Head and Neck in Intensity-modulated Radiotherapy Era Recruiting NCT03138642 Phase 2
14 Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma Recruiting NCT03313206 Phase 2 Pembrolizumab
15 Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma Recruiting NCT03241186 Phase 2 Ipilimumab;Nivolumab;Nivolumab
16 PLX3397 KIT in Acral aNd mucOsal Melanoma Recruiting NCT02071940 Phase 2 PLX3397
17 Bevacizumab Combined With Carboplatin Plus Paclitaxel Chemotherapy to Treat Metastatic Mucosal Melanoma Recruiting NCT02023710 Phase 2 Paclitaxel;Carboplatin;Bevacizumab
18 A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab Recruiting NCT02978443 Phase 2 Nivolumab;Ipilimumab
19 Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists Recruiting NCT02126579 Phase 1, Phase 2
20 Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma Patients Recruiting NCT03190824 Phase 2 OBP-301
21 Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib Recruiting NCT03235245 Phase 2 Nivolumab + Ipilimumab;Encorafenib + Binimetinib
22 Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma Recruiting NCT02748564 Phase 2
23 Nivolumab With or Without Ipilimumab or Relatlimab Before Surgery in Treating Patients With Stage IIIB-IV Melanoma That Can Be Removed by Surgery Recruiting NCT02519322 Phase 2
24 Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery Recruiting NCT03698019 Phase 2
25 Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery Active, not recruiting NCT00700882 Phase 2 dasatinib
26 Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery Active, not recruiting NCT02158520 Phase 2 Nab-paclitaxel
27 Dinaciclib in Treating Patients With Stage IV Melanoma Active, not recruiting NCT00937937 Phase 2 Dinaciclib
28 Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma Active, not recruiting NCT01827111 Phase 2 ABI-007;Ipilimumab
29 Phase II Study of Nivolumab in Combination With Radiation Therapy as Definitive Treatment for Patients With Locally Advanced, Unresectable Head and Neck Mucosal Melanoma. Not yet recruiting NCT03758729 Phase 2 Nivolumab
30 Study of the Combination of CM082 With JS001 in Patients With Advanced Mucinous Melanoma. Not yet recruiting NCT03602547 Phase 2 CM082 plus JS001
31 CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301 in Treating Patients With Stage IIB-IV Melanoma Suspended NCT02129075 Phase 2
32 Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma Terminated NCT01092728 Phase 2 Dasatinib
33 Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV Terminated NCT01166126 Phase 2 temsirolimus;selumetinib
34 Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients Terminated NCT00706992 Phase 2
35 A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma Terminated NCT01864538 Phase 2 TH-302
36 Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma Withdrawn NCT03220009 Phase 2
37 Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041) Completed NCT02180061 Phase 1
38 Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured Completed NCT00798629 Phase 1
39 Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases Recruiting NCT02858869 Phase 1
40 Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease Recruiting NCT03025256 Phase 1
41 Molecular Characterization of Primary Mucosal Melanoma Recruiting NCT03319693

Search NIH Clinical Center for Mucosal Melanoma

Genetic Tests for Mucosal Melanoma

Genetic tests related to Mucosal Melanoma:

# Genetic test Affiliating Genes
1 Mucosal Melanoma 29

Anatomical Context for Mucosal Melanoma

MalaCards organs/tissues related to Mucosal Melanoma:

41
Skin, T Cells, Lymph Node, Brain, Thymus, Cerebellum, Myeloid

The Foundational Model of Anatomy Ontology organs/tissues related to Mucosal Melanoma:

19
Mucosal Membranes Lining The Respiratory

Publications for Mucosal Melanoma

Articles related to Mucosal Melanoma:

(show top 50) (show all 328)
# Title Authors Year
1
Mucosal melanoma: clinical and genetic profile. ( 29797459 )
2018
2
Clinical patterns and management of primary mucosal melanoma: a single centre experience. ( 29388353 )
2018
3
Updates in the management of sinonasal mucosal melanoma. ( 29095708 )
2018
4
Mucosal Melanoma: a Literature Review. ( 29569184 )
2018
5
Anorectal mucosal melanoma. ( 29492238 )
2018
6
Approaches to regional lymph node metastasis in patients with head and neck mucosal melanoma. ( 29044491 )
2018
7
Primary sinonasal mucosal melanoma simulated as cystic lesions: a case report. ( 29535967 )
2018
8
Reply to mucosal melanoma: clinical and genetic profile. ( 29799644 )
2018
9
Contemporary Treatment Approaches to Sinonasal Mucosal Melanoma. ( 29492677 )
2018
10
Analysis of TSC1 mutation spectrum in mucosal melanoma. ( 29185092 )
2018
11
Multifactorial Analysis of Prognostic Factors and Survival Rates Among 706 Mucosal Melanoma Patients. ( 29748886 )
2018
12
Whole-exome sequencing of oral mucosal melanoma reveals mutational profile and therapeutic targets. ( 29230811 )
2018
13
Patterns of Treatment Failure in Patients with Sinonasal Mucosal Melanoma. ( 29626308 )
2018
14
A comprehensive genome-wide analysis of the long noncoding RNA expression profile in metastatic lymph nodes of oral mucosal melanoma. ( 29960071 )
2018
15
Immunotherapy in mucosal melanoma: a case report and review of the literature. ( 29707161 )
2018
16
<i>KIT, NRAS, BRAF</i> and <i>FMNL2</i> mutations in oral mucosal melanoma and a systematic review of the literature. ( 29805686 )
2018
17
Are oral mucosal nevi potential precursors for oral mucosal melanoma? ( 29501410 )
2018
18
Pseudoprogression with subsequent complete response and severe thrombocytopenia to checkpoint inhibitor immunotherapy in a patient with advanced mucosal melanoma of the sinonasal cavity. ( 29952773 )
2018
19
Genital mucosal melanoma with somatic SF3B1 R625C mutation. ( 29624176 )
2018
20
Combination therapy improves immune response and prognosis in patients with advanced oral mucosal melanoma: A clinical treatment success. ( 29958936 )
2018
21
Efficacy of nivolumab monotherapy against acral lentiginous melanoma and mucosal melanoma in Asian patients. ( 30447078 )
2018
22
The existence of early stage oral mucosal melanoma: A 10-year retrospective analysis of 170 patients in a single institute. ( 30527246 )
2018
23
Combatting mucosal melanoma: recent advances and future perspectives. ( 30459941 )
2018
24
Similar survival outcome after endoscopic and open approaches for sinonasal mucosal melanoma. ( 30471227 )
2018
25
SPRED1 Is a Tumor Suppressor in Mucosal Melanoma. ( 30413408 )
2018
26
The Pedunculated Pretender: A Case of Invasive Anorectal Mucosal Melanoma. ( 30454500 )
2018
27
Prognostic factors and incidence of primary mucosal melanoma: a population-based study in France. ( 30378540 )
2018
28
Human tumor genomics and zebrafish modeling identify SPRED1 loss as a driver of mucosal melanoma. ( 30385465 )
2018
29
Altered expression pattern of circular RNAs in metastatic oral mucosal melanoma. ( 30323971 )
2018
30
Predictors of mucosal melanoma survival in a population-based setting. ( 30296542 )
2018
31
The evaluation of malignant mucosal melanoma of nasal cavity with a rare occasion. ( 30245777 )
2018
32
Prognosis of endoscopic surgery and traditional open resection in mucosal melanoma of the nasal cavity and paranasal sinus. ( 30256270 )
2018
33
ASO Author Reflections: Treatment Approaches to Sinonasal Mucosal Melanoma. ( 30267288 )
2018
34
The Pedunculated Pretender: A Case of Invasive Anorectal Mucosal Melanoma. ( 30269709 )
2018
35
Successful treatment of metastatic mucosal melanoma with a Del579 c-KIT mutation by imatinib after treatment of anti-PD-1 antibody. ( 30199578 )
2018
36
Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. ( 30202085 )
2018
37
Primary Mucosal Melanoma of the Stomach. ( 30159179 )
2018
38
Primary and secondary mucosal melanoma of the small intestine - a clinical, pathological, and genetic nationwide survey of Danish patients between 1980 and 2014. ( 30160023 )
2018
39
Oral malignant gastrointestinal neuroectodermal tumour with junctional component mimicking mucosal melanoma. ( 30177220 )
2018
40
Primary malignant melanoma of esophagus shared similar genetic characters with both cutaneous and oral mucosal melanoma. ( 30023129 )
2018
41
Successful rechallenge with nivolumab therapy after radiotherapy in mucosal melanoma. ( 30035312 )
2018
42
Mucosal melanoma of the cranio-facial region: Surgical challenges and therapeutic options. ( 30082161 )
2018
43
Primary Middle Ear Mucosal Melanoma: Case Report and Comprehensive Literature Review of 21 Cases of Primary Middle Ear and Eustachian Tube Melanoma. ( 30103615 )
2018
44
Predominance of oral mucosal melanoma in areas of high mechanical stress. ( 30138653 )
2018
45
Radiotherapy alone as a method of treatment for sinonasal mucosal melanoma: A report based on six cases and a review of current opinion. ( 30147451 )
2018
46
The clinical significance of<i>c-Kit</i>mutations in metastatic oral mucosal melanoma in China. ( 29137292 )
2017
47
Mutational Status of NRAS and BRAF Genes and Protein Expression Analysis in a Series of Primary Oral Mucosal Melanoma. ( 28134726 )
2017
48
Long-term treatment outcomes and prognosis of mucosal melanoma of the head and neck: 161 cases from a single institution. ( 29103739 )
2017
49
Mucosal Melanoma Originating From the Eustachian Tube. ( 28953148 )
2017
50
Failure patterns and prognostic factors of patients with primary mucosal melanoma of the nasal cavity and paranasal sinuses. ( 28767022 )
2017

Variations for Mucosal Melanoma

Expression for Mucosal Melanoma

Search GEO for disease gene expression data for Mucosal Melanoma.

Pathways for Mucosal Melanoma

Pathways related to Mucosal Melanoma according to GeneCards Suite gene sharing:

(show all 44)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.95 BRAF GNA11 GNAQ IL2 KIT NF1
2
Show member pathways
13.66 BRAF GNA11 GNAQ IL2 KIT NRAS
3
Show member pathways
13.17 BRAF IL2 KIT NF1 NRAS
4
Show member pathways
13.02 BRAF GNA11 GNAQ IL2 NRAS
5
Show member pathways
12.82 IL2 KIT NRAS TERT
6
Show member pathways
12.8 BRAF GNA11 IL2 KIT NRAS
7
Show member pathways
12.62 BRAF GNA11 GNAQ KIT NRAS
8
Show member pathways
12.6 BRAF GNA11 MITF NRAS
9
Show member pathways
12.59 BRAF MITF NF1 NRAS
10 12.58 BRAF KIT NF1 NRAS
11
Show member pathways
12.57 BRAF KIT NRAS TERT
12
Show member pathways
12.51 BRAF GNA11 GNAQ NRAS
13
Show member pathways
12.44 BRAF GNAQ KIT NF1 NRAS
14
Show member pathways
12.27 BRAF MITF NRAS
15 12.26 IL2 NRAS TERT
16
Show member pathways
12.22 BRAF IL2 KIT NRAS
17
Show member pathways
12.13 BRAF NF1 NRAS
18
Show member pathways
12.09 BRAF MITF NRAS
19
Show member pathways
12.05 BRAF GNA11 GNAQ NRAS
20
Show member pathways
12.04 BRAF GNAQ NRAS
21 11.95 BRAF GNA11 GNAQ IL2 KIT MITF
22
Show member pathways
11.89 BRAF NF1 NRAS
23
Show member pathways
11.88 GNA11 GNAQ NRAS
24
Show member pathways
11.84 BRAF GNA11 GNAQ KIT MITF NRAS
25
Show member pathways
11.83 BRAF GNA11 GNAQ
26 11.78 BRAF GNAQ NRAS
27 11.76 BRAF NF1 NRAS
28 11.73 BRAF GNA11 GNAQ
29 11.72 BRAF GNAQ NF1 NRAS
30 11.6 GNA11 GNAQ NRAS
31
Show member pathways
11.53 BRAF KIT NRAS
32 11.53 BRAF GNA11 GNAQ IL2
33 11.41 BRAF GNA11 GNAQ IL2 NRAS
34 11.31 BRAF NRAS
35 11.3 KIT MITF
36 11.27 GNA11 GNAQ
37 11.24 BRAF GNA11 NRAS
38 11.23 BRAF GNA11 GNAQ NRAS
39 11.22 GNA11 GNAQ
40 11.2 GNA11 GNAQ
41 11.2 BRAF NRAS
42 11.09 GNA11 GNAQ NRAS
43 10.93 GNAQ NRAS
44
Show member pathways
10.8 GNA11 GNAQ

GO Terms for Mucosal Melanoma

Cellular components related to Mucosal Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heterotrimeric G-protein complex GO:0005834 8.62 GNA11 GNAQ

Biological processes related to Mucosal Melanoma according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 9.99 BRAF GNA11 GNAQ KIT NF1 NRAS
2 negative regulation of apoptotic process GO:0043066 9.72 BRAF IL2 KIT MITF TERT
3 T cell differentiation GO:0030217 9.56 IL2 KIT
4 negative regulation of endothelial cell apoptotic process GO:2000352 9.55 BRAF TERT
5 response to cadmium ion GO:0046686 9.54 KIT TERT
6 melanocyte differentiation GO:0030318 9.52 KIT MITF
7 action potential GO:0001508 9.49 GNA11 GNAQ
8 G protein-coupled acetylcholine receptor signaling pathway GO:0007213 9.48 GNA11 GNAQ
9 developmental pigmentation GO:0048066 9.46 GNA11 KIT
10 regulation of cell proliferation GO:0042127 9.46 BRAF KIT MITF NF1
11 phototransduction, visible light GO:0007603 9.43 GNA11 GNAQ
12 visual learning GO:0008542 9.43 BRAF KIT NF1
13 entrainment of circadian clock GO:0009649 9.4 GNA11 GNAQ
14 myeloid progenitor cell differentiation GO:0002318 9.37 BRAF KIT
15 pigmentation GO:0043473 9.13 KIT MITF NF1
16 MAPK cascade GO:0000165 9.02 BRAF IL2 KIT NF1 NRAS

Molecular functions related to Mucosal Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G-protein beta/gamma-subunit complex binding GO:0031683 9.16 GNA11 GNAQ
2 guanyl nucleotide binding GO:0019001 8.96 GNA11 GNAQ
3 type 2A serotonin receptor binding GO:0031826 8.62 GNA11 GNAQ

Sources for Mucosal Melanoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....